{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T01:46:53Z","timestamp":1769910413817,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Ministry of Health, Labour, and Welfare of Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s12185-021-03197-5","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T13:02:41Z","timestamp":1626958961000},"page":"415-423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Strong association between insufficient plasma exchange and fatal outcomes in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura"],"prefix":"10.1007","volume":"114","author":[{"given":"Michinori","family":"Kayashima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Kanetake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinta","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7243-3126","authenticated-orcid":false,"given":"Masanori","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"key":"3197_CR1","doi-asserted-by":"publisher","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","volume":"3","author":"JA Kremer Hovinga","year":"2017","unstructured":"Kremer Hovinga JA, Coppo P, Lammle B, Moake JL, Miyata T, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura. Nat Rev Dis Prim. 2017;3:17020.","journal-title":"Nat Rev Dis Prim"},{"issue":"10","key":"3197_CR2","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1182\/blood-2017-04-636431","volume":"130","author":"JE Sadler","year":"2017","unstructured":"Sadler JE. Pathophysiology of thrombotic thrombocytopenic purpura. Blood. 2017;130(10):1181\u20138.","journal-title":"Blood"},{"issue":"44","key":"3197_CR3","doi-asserted-by":"publisher","first-page":"41059","DOI":"10.1074\/jbc.C100515200","volume":"276","author":"X Zheng","year":"2001","unstructured":"Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276(44):41059\u201363.","journal-title":"J Biol Chem"},{"issue":"Suppl 1","key":"3197_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1538-7836.2011.04341.x","volume":"9","author":"Y Fujimura","year":"2011","unstructured":"Fujimura Y, Matsumoto M, Isonishi A, Yagi H, Kokame K, Soejima K, et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost. 2011;9(Suppl 1):283\u2013301.","journal-title":"J Thromb Haemost"},{"issue":"6855","key":"3197_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/35097008","volume":"413","author":"GG Levy","year":"2001","unstructured":"Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488\u201394.","journal-title":"Nature"},{"issue":"22","key":"3197_CR6","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","volume":"339","author":"M Furlan","year":"1998","unstructured":"Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339(22):1578\u201384.","journal-title":"N Engl J Med"},{"issue":"22","key":"3197_CR7","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","volume":"339","author":"HM Tsai","year":"1998","unstructured":"Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339(22):1585\u201394.","journal-title":"N Engl J Med"},{"issue":"1","key":"3197_CR8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1182\/asheducation-2015.1.631","volume":"2015","author":"JE Sadler","year":"2015","unstructured":"Sadler JE. What\u2019s new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura. Hematol Am Soc Hematol Educ Progr. 2015;2015(1):631\u20136.","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"issue":"6","key":"3197_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJM199108083250604","volume":"325","author":"GA Rock","year":"1991","unstructured":"Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325(6):393\u20137.","journal-title":"N Engl J Med"},{"issue":"2","key":"3197_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/00005792-196603000-00003","volume":"45","author":"EL Amorosi","year":"1966","unstructured":"Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1966;45(2):139\u201359.","journal-title":"Medicine"},{"issue":"1","key":"3197_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-017-2264-7","volume":"106","author":"M Matsumoto","year":"2017","unstructured":"Matsumoto M, Fujimura Y, Wada H, Kokame K, Miyakawa Y, Ueda Y, et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. Int J Hematol. 2017;106(1):3\u201315.","journal-title":"Int J Hematol"},{"issue":"3","key":"3197_CR12","doi-asserted-by":"publisher","first-page":"e33029","DOI":"10.1371\/journal.pone.0033029","volume":"7","author":"M Matsumoto","year":"2012","unstructured":"Matsumoto M, Bennett CL, Isonishi A, Qureshi Z, Hori Y, Hayakawa M, et al. Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan. PLoS One. 2012;7(3):e33029.","journal-title":"PLoS One"},{"issue":"4","key":"3197_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully M, Cataland SR, Peyvandi F, Coppo P, Knobl P, Kremer Hovinga JA, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335\u201346.","journal-title":"N Engl J Med"},{"issue":"10","key":"3197_CR14","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1111\/trf.13182","volume":"55","author":"A Isonishi","year":"2015","unstructured":"Isonishi A, Bennett CL, Plaimauer B, Scheiflinger F, Matsumoto M, Fujimura Y. Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasma. Transfusion. 2015;55(10):2321\u201330.","journal-title":"Transfusion"},{"issue":"1","key":"3197_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2169\/internalmedicine.49.2706","volume":"49","author":"Y Fujimura","year":"2010","unstructured":"Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998\u20132008. Intern Med. 2010;49(1):7\u201315.","journal-title":"Intern Med"},{"issue":"8","key":"3197_CR16","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1111\/j.1537-2995.2006.00914.x","volume":"46","author":"S Kato","year":"2006","unstructured":"Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion. 2006;46(8):1444\u201352.","journal-title":"Transfusion"},{"issue":"11","key":"3197_CR17","doi-asserted-by":"publisher","first-page":"e0143136","DOI":"10.1371\/journal.pone.0143136","volume":"10","author":"N Nishigori","year":"2015","unstructured":"Nishigori N, Matsumoto M, Koyama F, Hayakawa M, Hatakeyayama K, Ko S, et al. von Willebrand factor-rich platelet thrombi in the liver cause sinusoidal obstruction syndrome following oxaliplatin-based chemotherapy. PLoS ONE. 2015;10(11):e0143136.","journal-title":"PLoS ONE"},{"issue":"3","key":"3197_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"3197_CR19","first-page":"21","volume":"24","author":"E Moschcowitz","year":"1924","unstructured":"Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Y Pathol Soc. 1924;24:21\u20134.","journal-title":"Proc N Y Pathol Soc"},{"issue":"7","key":"3197_CR20","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","volume":"118","author":"M Scully","year":"2011","unstructured":"Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118(7):1746\u201353.","journal-title":"Blood"},{"key":"3197_CR21","doi-asserted-by":"publisher","first-page":"107602961882530","DOI":"10.1177\/1076029618825309","volume":"25","author":"W Owattanapanich","year":"2019","unstructured":"Owattanapanich W, Wongprasert C, Rotchanapanya W, Owattanapanich N, Ruchutrakool T. Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. Clin Appl Thromb Hemost. 2019;25:1076029618825309.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"3197_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","volume":"40","author":"A Froissart","year":"2012","unstructured":"Froissart A, Buffet M, Veyradier A, Poullin P, Prov\u00f4t F, Malot S, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012;40(1):104\u201311.","journal-title":"Crit Care Med"},{"issue":"14","key":"3197_CR23","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/blood.2020009150","volume":"137","author":"A Cuker","year":"2021","unstructured":"Cuker A, Cataland SR, Coppo P, de la Rubia J, Friedman KD, George JN, et al. Redefining outcomes in immune TTP: an international working group consensus report. Blood. 2021;137(14):1855\u201361.","journal-title":"Blood"},{"issue":"7","key":"3197_CR24","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1046\/j.1538-7836.2003.00260.x","volume":"1","author":"ZM Ruggeri","year":"2003","unstructured":"Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost. 2003;1(7):1335\u201342.","journal-title":"J Thromb Haemost"},{"issue":"9","key":"3197_CR25","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1182\/blood-2014-05-378638","volume":"124","author":"TA Springer","year":"2014","unstructured":"Springer TA. von Willebrand factor, Jedi knight of the bloodstream. Blood. 2014;124(9):1412\u201325.","journal-title":"Blood"},{"issue":"8","key":"3197_CR26","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3324\/haematol.2011.049676","volume":"97","author":"Y Benhamou","year":"2012","unstructured":"Benhamou Y, Assi\u00e9 C, Boelle PY, Buffet M, Grillberger R, Malot S, et al. Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica. 2012;97(8):1181\u20136.","journal-title":"Haematologica"},{"issue":"2","key":"3197_CR27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/jth.12790","volume":"13","author":"Y Benhamou","year":"2015","unstructured":"Benhamou Y, Boelle PY, Baudin B, Ederhy S, Gras J, Galicier L, et al. Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center. J Thromb Haemost. 2015;13(2):293\u2013302.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"3197_CR28","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knobl P, Wu H, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374(6):511\u201322.","journal-title":"N Engl J Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03197-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-021-03197-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03197-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T12:16:30Z","timestamp":1631189790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-021-03197-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["3197"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03197-5","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,22]]},"assertion":[{"value":"25 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M. Matsumoto is a member of the clinical advisory board of Takeda Yakuhin and Sanofi. He is also an inventor of the ADAMTS13 act-ELISA. The remaining authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}